IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01865435
• Other study ID #: 2012-A01655-38
• Secondary ID: 2012-52
• Status: Completed
• Phase: N/A
• First received: May 27, 2013
• Last updated: September 29, 2015
• Start date: March 2014
• Est. completion date: April 2015

Study information

• Verified date: September 2015
• Source: Assistance Publique Hopitaux De Marseille
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

Actually, there is an increasing number of arguments for a premature origin of chronic adult's diseases, as the chronic obstructive pulmonary disease (COPD). Several factors interacting with the foetal or postnatal lung growth are associated with early and long-lasting respiratory functional changes susceptible to contribute very significantly to the arisen of a COPD in the adulthood. It is possible that these situations reflect phenomena of premature cellular senescence, recently involved in the physiopathology of the COPD. An in utero exposition to cigarette smoking is one of these situations, because it is known to induce, not only functional respiratory changes, but also multiple diseases in the child which could testify of cellular ageing phenomena.

Our project aims to demonstrate that in utero smoking is associated with markers of premature cellular senescence in newborn children

The study will be driven in human newborn child's, with comparison of the length of the telomeres in circulating lymphocytes (umbilical blood is collected), according to the exposure in in utero smoking and also according to the degree of hypotrophy. This study will be a pilot study completed by an animal experimental study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 27 Days

Eligibility

Inclusion Criteria:

• Born weight upper or equal to the 10th percentile and absence of smoking declared by the mother

• Born weight lower than the 10th percentile and absence of smoking declared by the mother

• Born weight upper or equal to the 10th percentile and smoking declared by the mother of at least 5 cigarettes a day

• Born weight lower than the 10th percentile and smoking declared by the mother of at least 5 cigarettes a day

Exclusion Criteria:

• Gestationnel age 37 LIMITED COMPANIES

• Low(Weak) declaratory(declarative) maternal smoking (1 in 4 cigarettes a day)

• Pathologies associated by the newborn child (deformations, foetal suffering, infection maternofœtale, respiratory distress syndrome)

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Genetic:
• cord blood sample

Locations

Country	Name	City	State
France	Assistance Publique Hopitaux de Marseille	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cord blood samples		12months	No